Trial Profile
ASPIRE: DETERIMINING THE IMPACT OF CRISABOROLE (Eucrisa) AND TACROLIMUS 0.03% ON PATIENT-REPORTED OUTCOMES AND CAREGIVER BURDEN IN CHILDREN WITH ATOPIC DERMATITIS
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 02 Nov 2022
Price :
$35
*
At a glance
- Drugs Crisaborole (Primary) ; Tacrolimus (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Acronyms ASPIRE
- 08 Sep 2021 Status changed from recruiting to completed.
- 10 Aug 2021 Planned End Date changed from 30 Jul 2021 to 31 Oct 2021.
- 10 Aug 2021 Planned primary completion date changed from 30 Jul 2021 to 31 Aug 2021.